Premium
Current Drug Scheduling Reviews Reported by the DEA
Author(s) -
Walker Michelle D,
Prioleau Cassandra,
Ghozland Sandy,
Boos Terrence,
Tella Srihari,
Sannerud Christine
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.623.2
Aims As mandated by the Controlled Substances Act (CSA), DEA collects and reviews scientific, medical and other data for substances with abuse potential to determine the appropriate control status for placement into one of five schedules. Methods Administrative process for scheduling is currently ongoing for carisoprodol, dextromethorphan, Salvinorin A and hallucinogens such as 5‐MeO‐DMT, 5‐MeO‐AMT, 5‐MeO‐DET, 5‐MeO‐MIPT, DIPT, and 4‐OH‐DIPT. Administrative process for several petitions requesting control of propofol, decontrol of 6‐beta‐naltrexol and amendment to CFR so as to allow generic products of dronabinol in sesame oil into schedule III. Results DEA is currently reviewing the data for hallucinogens such as 2C‐I, 2C‐T‐2, and DOI for possible control. Chemical synthesis/pharmacological studies for DOC, 2C‐C, 2C‐D, and 2C‐E are currently ongoing to determine if these substances require control. Conclusions Administrative process for scheduling is completed for tapentadol, lacosamide and fospropofol. Support: DEA